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iNO = inhaled nitric oxide; LPD = low potassium dextran.
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The case report by Della Rocca and coworkers published in
this issue of Critical Care [1] describes the occurrence of
severe reperfusion injury after lung transplantation and
successful treatment using a combination of inhaled nitric
oxide (iNO) and surfactant instillation. What is the role of
surfactant in management of initially impaired graft function
after lung transplantation, and do these findings apply to
other forms of lung injury?
Ischaemia/reperfusion injury leading to initial graft failure is a
major cause of early mortality after lung transplantation. In
addition, this problem led to the exclusion of most organ
donors from lung harvesting, because acceptance criteria
selected only optimal grafts. A shortage of suitable lung
grafts became the rate-limiting step to lung transplantation
[2]. Numerous studies were performed to avoid or ameliorate
ischaemia/reperfusion injury. As early as 1991, Novick and
coworkers [3] reported on alterations in surface activity of
surfactant in experimental lung transplantation. Subsequent
work [4] revealed an increase in serum protein associated
with an increased small aggregate/large aggregate ratio in
lavage of transplanted lungs. This finding led to the
hypothesis that leakage of plasma protein into the alveolar
space may inhibit surface-active large surfactant aggregates.
In order to deal with this problem, two courses of action were
considered. One is to substitute surface-active surfactant,
and the other is to prevent plasma protein leakage into the
alveolar space. In 1995 we were the first to report successful
clinical treatment of reperfusion injury in a lung transplant
recipient by administration of exogenous surfactant [5],
followed by a review of six consecutive patients with
established severe ischaemia/reperfusion injury [6]. Because
a prospective clinical trial of surfactant substitution in lung
transplantation is not available, these clinical observations are
supported only by animal studies [7].
Methods to prevent ischaemia/reperfusion injury and
pulmonary oedema were the subject of numerous studies.
The use of iNO as a means to ameliorate such injury by
reduction in pulmonary vascular resistance, leucocyte
sequestration in the lung and improvement in gas exchange
emerged from laboratory investigations [8]. Therefore, many
lung transplant programmes use iNO routinely during early
reperfusion of the lung. Bearing in mind that the concept of
ischaemia/reperfusion injury in clinical transplantation also
embodies the state of the donor lung before harvesting and
the quality of preservation, the method of lung procurement
must be considered.
Antegrade cold flush perfusion using cold Euro-Collins
solution became the standard method of lung procurement
10–15 years ago [9]. Euro-Collins is a solution of intracellular
ion composition that was originally developed for kidney
preservation. Deleterious effects of this solution on the
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Abstract
Although numerous studies over the past 40 years have addressed this problem, initial graft failure is
still a key question in clinical lung transplantation. As a possible tool to avoid and treat initial graft failure
after lung transplantation, laboratory evidence and clinical reports currently emphasize the role of
substitution therapy of surfactant combined with inhaled nitric oxide.
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surfactant system were frequently reported [10].
Experimentally, it was shown that a preservation solution
composed of extracellular ions might improve early graft
function, particularly when dextran was added as an oncotic
agent. The so-called low potassium dextran (LPD) solution
improved surfactant function in an ischaemia/reperfusion
model in minipigs by preventing plasma leakage [11]. A
further improvement in graft function and better maintenance
of the small aggregate/large aggregate ratio was found when
the LPD solution was flushed retrograde through the graft
[12]. Therefore, many major lung transplant centres
abandoned the Euro-Collins technique and started to use
LPD or other extracellular solutions instead. A lesser
incidence as well as lesser severity of ischaemia/reperfusion
injury and a reduction in requirement for early
retransplantation have been reported [13,14].
The case reported by Della Rocca and coworkers [1]
represents a typical report of severe reperfusion injury in a
graft preserved in Euro-Collins solution, with an ischaemic
time of 6 hours or more. In our experience, Euro-Collins
preserved lungs are especially prone to reperfusion injury
when extracorporeal circulation is used during the procedure.
We observed a prolonged ventilation period in such patients
after lung transplantation as a result of reperfusion injury, and
we therefore changed the perfusion solution from Euro-
Collins to LPD (Fig. 1). According to the case report [1],
extracorporeal circulation was instituted when right heart
failure occurred after implantation of the left lung and
clamping of the contralateral pulmonary artery, despite iNO
and prostaglandin E1 treatment. However, it does not
indicate for how long the first transplanted lung was
reperfused when the pulmonary artery was clamped.
Increased pulmonary vascular resistance is a common
phenomenon in early reperfusion. For this reason, many
surgeons prefer to transplant the right lung first, and to
employ a prolonged reperfusion time after implantation of the
first lung before clamping the contralateral pulmonary artery.
There are case reports and small studies of the successful
use of iNO and surfactant replacement in adult respiratory
distress syndrome patients. However, both therapeutic
strategies failed to show efficacy in prospective randomized
trials, so what justification is there for the use of these
approaches in lung transplantation? A body of evidence has
been established that indicates that surfactant function after
lung transplantation is reduced in all cases. However, after an
uncomplicated lung transplant procedure, lung function starts
to improve following completion of surgery and is usually
best 3–6 months after transplantation. In the cases of graft
failure, brain death and infection of the donor lung, reduced
surfactant function is aggravated by preservation of the graft,
ischaemia and reperfusion. Therefore, substitution of
surfactant may bridge the patient to recovery of the graft. The
combination of iNO and surfactant proved to be successful
in experimental severe reperfusion injury [15], strengthening
the hypothesis that this combination prevents intrapulmonary
shunt more effectively than does either intervention alone,
and that it reduces inactivation of surfactant substitutes.
In summary, we emphasize that surfactant function should be
considered when a preservation method is selected for lung
procurement. In addition, combined iNO and surfactant
replacement may be effective in graft failure after lung
transplantation, and should be used before indications for
extracorporeal membrane oxygenation or retransplantation
are considered. This interesting approach was successful in
the experimental setting of acute lung injury and needs to be
verified in clinical indications other than lung transplantation.
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